Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response

SIMPLE SUMMARY: Malignant Pleural Mesothelioma (MPM) is a highly aggressive, therapy-resistant cancer with a well-established inflammatory etiology and has no cure. Immune checkpoint inhibition (ICI) therapy has shifted treatment paradigms in many types of cancers, and recent clinical data have show...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmanbeyoglu, Hatice Ulku, Palmer, Drake, Sagan, April, Sementino, Eleonora, Becich, Michael J., Testa, Joseph R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688367/
https://www.ncbi.nlm.nih.gov/pubmed/36428720
http://dx.doi.org/10.3390/cancers14225626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688367/
https://www.ncbi.nlm.nih.gov/pubmed/36428720
http://dx.doi.org/10.3390/cancers14225626

Ejemplares similares